The potential role of glucose metabolism, lipid metabolism, and amino acid metabolism in the treatment of Parkinson's disease.

PURPOSE OF REVIEW: Parkinson's disease (PD) is a common neurodegenerative disease, which can cause progressive deterioration of motor function causing muscle stiffness, tremor, and bradykinesia. In this review, we hope to describe approaches that can improve the life of PD patients through modifications of energy metabolism. RECENT FINDINGS: The main pathological features of PD are the progressive loss of nigrostriatal dopaminergic neurons and the production of Lewy bodies. Abnormal aggregation of α-synuclein (α-Syn) leading to the formation of Lewy bodies is closely associated with neuronal dysfunction and degeneration. The main causes of PD are said to be mitochondrial damage, oxidative stress, inflammation, and abnormal protein aggregation. Presence of abnormal energy metabolism is another cause of PD. Many studies have found significant differences between neurodegenerative diseases and metabolic decompensation, which has become a biological hallmark of neurodegenerative diseases. SUMMARY: In this review, we highlight the relationship between abnormal energy metabolism (Glucose metabolism, lipid metabolism, and amino acid metabolism) and PD. Improvement of key molecules in glucose metabolism, fat metabolism, and amino acid metabolism (e.g., glucose-6-phosphate dehydrogenase, triglycerides, and levodopa) might be potentially beneficial in PD. Some of these metabolic indicators may serve well during the diagnosis of PD. In addition, modulation of these metabolic pathways may be a potential target for the treatment and prevention of PD.

Mechanism of morusin on breast cancer via network pharmacology and in vitro experiments.

BACKGROUND: This study aimed to investigate the therapeutic effect of morusin on breast cancer and decode its underlying molecular mechanism using network pharmacology and in vitro techniques. METHODS: Swiss Target Prediction and PharMmapper were applied to screen morusin targets. The targets of human breast cancer were obtained from the GeneCards database, and the overlapping targets were screened. A protein-protein interaction network was constructed based on the overlapping targets by String and Cytoscape. Performed Gene Ontology enrichment as well as Kyoto Encyclopedia of Genes and Genomes pathway enrichment analysis on the shared targets of the drug and disease using the David database. Additionally, performed molecular docking using PyMoL and AutoDock software. Finally, the impact of morusin on breast cancer was demonstrated by cell experiments and western blot. RESULTS: A total of 101 target genes were obtained through screening including ESR1, EGFR, ALB, CTNNB1, AKT1, and so on. Based on the annotation of Gene Ontology and Kyoto Encyclopedia of Genes and Genomes enrichment analysis, the anticancer properties of morusin are linked to apoptosis, migration, and PI3K-AKT signaling pathways. Molecular docking showed an interaction between morusin and PIK3CA, AKT1. In vitro data demonstrated that morusin causes apoptosis and inhibits cell migration. Morusin also increased the expression of cleaved-PARP while decreasing the expression of p-PI3K and p-AKT. CONCLUSION: Through network pharmacology analysis and in vitro experiments, this study showed that morusin promotes apoptosis and inhibits migration by modulating the PI3K-AKT axis. Morusin plays a key role in the treatment of breast cancer.